Skip to main content
. 2020 Jan 8;69(4):681–688. doi: 10.2337/db19-0770

Figure 2.

Figure 2

Percentage change from baseline in total EGP measured with [3-3H]glucose infusion in subjects receiving dapagliflozin or placebo in study 1 (A), study 2 (glucose clamp) (C), and study 3 (pancreatic clamp) (E). The change in EGP from baseline to the last hour of the study is depicted in B (study 1), D (study 2), and F (study 3).